Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(88%)
Results Posted
200%(2 trials)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
3
38%
Ph phase_4
1
13%

Phase Distribution

0

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
3(37.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Completed(1)

Detailed Status

Active, not recruiting5
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (50.0%)
Phase 33 (37.5%)
Phase 41 (12.5%)

Trials by Status

completed113%
recruiting225%
active_not_recruiting563%

Recent Activity

7 active trials
Showing 5 of 8
active_not_recruitingphase_2

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895
active_not_recruitingphase_2

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025
recruitingphase_2

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
active_not_recruitingphase_3

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893
recruitingphase_4

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06550895Phase 2

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

Active Not Recruiting
NCT06577025Phase 2

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT07149857Phase 2

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Recruiting
NCT04923893Phase 3

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Active Not Recruiting
NCT05201781Phase 4

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Recruiting
NCT04181827Phase 3

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Active Not Recruiting
NCT05257083Phase 3

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT05347485Phase 2

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8